H.C. Wainwright Starts Aldeyra Therapeutics (ALDX) at Buy

September 26, 2016 7:36 AM EDT
Get Alerts ALDX Hot Sheet
Price: $5.55 -3.48%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade ALDX Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

H.C. Wainwright initiates coverage on Aldeyra Therapeutics (NASDAQ: ALDX) with a Buy rating and a price target of $18.00.

Analyst Corey Davis commented, "As our title implies, we think few on Wall Street appreciate just how large a role that aldehydes play in myriad different disorders and hence how large the market could be for Aldeyra's NS2 "aldehyde trap". Aldeyra figured out the target, the solution, and now has three successful Phase 2 trials to boot. Aldehydes are a heterogenous group of compounds that are ubiquitous in living organisms. But since they are toxic (causing oxidative stress and inflammation), natural enzymes normally degrade them. However, when certain systems malfunction, aldehydes can accumulate and cause an array of problems. NS2 "traps" these toxic aldehydes and shuttles them to the lysosome for degradation thereby enhancing the body's normal elimination mechanism."

  • Sjorgren-Larsson Syndrome.
  • Allergic conjunctivitis would be huge market.
  • NS2 works in uveitis too.
  • Succinic semi-aldehyde dehydrogenase (SSADH) deficiency.
  • Our target is $18.

For an analyst ratings summary and ratings history on Aldeyra Therapeutics click here. For more ratings news on Aldeyra Therapeutics click here.

Shares of Aldeyra Therapeutics closed at $7.45 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

H.C. Wainwright

Add Your Comment